EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Curative or non-curative: immunotherapy for advanced melanoma

Richard Kelly iD, Abigail Miller iD, Rachel Roberts-Thomson, Andrew Haydon iD

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf041 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Richard Kelly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Paula Fox Melanoma and Cancer Centre, The Alfred, Melbourne, Australia. Hauptthemen laut MEDLINE: Melanoma, Immunotherapy, Skin Neoplasms. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Government Research Training Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced melanoma was historically considered incurable; however, a 52% 10-year melanoma-specific survival rate from seminal immunotherapy trials challenges that conclusion.1 There is no literature exploring clinicians’ discussion of treatment intent with patients, or whether this represents cure. We performed a multicenter retrospective cohort analysis to examine treatment intent, using electronic medical records to identify 278 patients with unresectable or stage IV melanoma consented for immunotherapy from 2019 to 2023. Thirty-two (12%) were consented for curative-intent treatment (CIT). CIT frequency was not significantly influenced by patient or disease characteristics. Patients consented for CIT received significantly higher rates of combination immunotherapy than patients consented for non-curative-intent treatment (NCIT), 76% (16/21) vs 47% (116/246), P = .022. Among 267 unresectable patients, CIT rates differed significantly between Victoria and South Australia, 14% (20/142) vs 0.8% (1/125), P < .001. Our data confirms variability of documented treatment-intent in advanced melanoma. Further research is needed to understand how this affects patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmunotherapySkin NeoplasmsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultAged, 80 and overNeoplasm StagingImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Paula Fox Melanoma and Cancer Centre, The Alfred, Melbourne, Australia.
  • The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • The Queen Elizabeth Hospital, Central Adelaide Local Health Network, Adelaide, South Australia.

ORCID-Profile: Richard Kelly, Abigail Miller, Andrew Haydon

Förderung

  • Australian Government Research Training Program

Zitieren

APA

Kelly, R., Miller, A., Roberts-Thomson, R., & Haydon, A. (2025). Curative or non-curative: immunotherapy for advanced melanoma. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf041

Vancouver

Kelly R, Miller A, Roberts-Thomson R, Haydon A. Curative or non-curative: immunotherapy for advanced melanoma. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf041

BibTeX
@article{Kelly2025,
  author = {Kelly, Richard and Miller, Abigail and Roberts-Thomson, Rachel and Haydon, Andrew},
  title = {Curative or non-curative: immunotherapy for advanced melanoma},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf041}
}
Kostenlos starten →